肾结核 中国就医指南

Renal tuberculosis (RTB) is a chronic, granulomatous infection of the kidney caused by Mycobacterium tuberculosis, typically resulting from hematogenous dissemination from a primary pulmonary focus. Unlike pulmonary TB, renal TB is almost always secondary and often remains asymptomatic for years due to its indolent progression. The pathogenesis begins with seeding of tubercle bacilli into the renal cortex via the bloodstream, followed by latent dormancy. Reactivation leads to caseating granulomas, cortical necrosis, and eventual spread to the medulla, calyces, and pelvis—causing ulceration, strictures, and cavitation. As disease advances, it may involve the ureters (causing stenosis and hydroureter) and bladder (inducing contracture, reduced capacity, and irritative symptoms). Epidemiologically, renal TB accounts for approximately 15–20% of all extrapulmonary TB cases globally, with higher prevalence in low- and middle-income countries where TB burden is substantial. In China, it represents ~5–10% of extrapulmonary TB admissions in nephrology departments, particularly among adults aged 30–55 years; incidence correlates strongly with regional TB prevalence and socioeconomic determinants such as overcrowding, malnutrition, and limited healthcare access. Key risk factors include untreated or inadequately treated pulmonary TB, HIV co-infection (increasing reactivation risk 20-fold), diabetes mellitus, immunosuppressive therapy (e.g., corticosteroids, biologics), end-stage renal disease, and prior urological instrumentation. Clinically, early RTB is frequently silent; later manifestations include sterile pyuria, microscopic hematuria, low-grade fever, flank pain, nocturia, and progressive renal dysfunction. Without timely intervention, irreversible parenchymal destruction, hypertension, chronic kidney disease (CKD), and even end-stage renal disease (ESRD) may ensue. Quality of life is significantly impaired—not only due to physical symptoms like fatigue, pain, and urinary frequency but also because of prolonged treatment duration, stigma associated with TB, diagnostic delays leading to anxiety and depression, and socioeconomic strain from lost workdays and caregiving demands. Patients often experience diminished sexual function, sleep disruption, and social withdrawal, especially in cultures where TB carries strong social stigma. Early diagnosis remains challenging due to nonspecific urinalysis findings and low sensitivity of urine AFB smears; nucleic acid amplification tests (NAATs) and urine mycobacterial culture are gold standards but require specialized labs and time. Multidisciplinary management involving nephrologists, infectious disease specialists, and urologists is essential to preserve renal function and prevent transmission.

# 肾结核治疗方案与详细费用明细（肾内科）

一、非手术/药物保守治疗（初治、单侧轻中度病变）

• •适用人群：菌阳或菌阴但影像学提示早期肾实质浸润、无明显空洞/钙化、肾功能正常（eGFR ≥60 mL/min/1.73m²）
• •方案：标准四联抗结核（异烟肼+利福平+吡嗪酰胺+乙胺丁醇），疗程≥9个月；全程督导服药+肝肾功能监测
• •费用明细（公立三甲医院，RMB）：

- 必查项目（尿抗酸染色×3、尿结核菌培养+药敏、CTU/IVP、血清肌酐/ALT/AST）：2,200–3,600元 - 门诊随访（含每月尿常规、肝肾功、视力筛查*注：非眼科，仅排除乙胺丁醇视神经毒性）：1,200–1,800元

二、手术/介入治疗（局限性毁损、耐药灶、梗阻性肾积水）

• •适用人群：单侧肾实质广泛破坏、肾盂输尿管狭窄伴重度积水、药物治疗失败或耐药
• •方案：腹腔镜下肾切除术（首选）或经皮穿刺引流+局部灌注（限脓肿型）
• •费用明细（RMB）：

- 手术费+麻醉+住院（7–10天）：28,000–42,000元（含国产耗材） - 微创介入（超声引导穿刺+异烟肼灌注）：12,500–18,000元/疗程

三、特殊复杂方案（耐药/双肾受累/终末期）

• •多药耐药（MDR-TB）：贝达喹啉+利奈唑胺+氯法齐明方案，全程18–24个月；费用：156,000–220,000元（含专项检测及不良反应管理）
• •双肾结核伴CKD 4–5期：抗结核联合血液透析过渡，择期肾移植（需结核完全控制≥12个月）；移植前结核清除总费用：280,000–350,000元

方案快速选择指南

• •预算≤1万元+初诊无并发症 → 首选药物保守治疗
• •预算2万–5万元+单侧结构破坏 → 腹腔镜肾切除术
• •耐药/双肾病变/透析依赖 → 转结核专科中心启动MDR方案+多学科管理